Agaricus Blazei Mushroom and Cancer Research

This page exists because Agaricus blazei is often marketed for cancer, and readers deserve a clear, honest account of what the science does and does not support. The short version: Agaricus blazei has been studied mainly in laboratory dishes and in mice, where its beta-glucans activate anti-tumor immune cells; the human evidence amounts to a small number of preliminary trials, most measuring immune markers or quality of life rather than survival or tumor shrinkage. There is no reliable evidence that Agaricus blazei cures, treats, or shrinks cancer in people, and it must never replace conventional cancer care. What follows explains the actual findings, their mechanisms, and their limits — including a genuine safety signal (liver injury) reported in cancer patients.

The Bottom Line, Stated First
Why This Mushroom Became a Cancer-Research Subject
Preclinical Evidence: Cell and Animal Tumor Models
The Proposed Mechanism: Immunity, Not Direct Cytotoxicity
Chemoprevention and Genotoxicity Studies
A Mixed Picture: When the Mushroom Did Nothing
The Human Trial People Cite — and Its Limits
What the Research Does NOT Show
Safety in Cancer Patients (Including Liver Injury)
Talking With Your Oncology Team
Key Research Papers
External Resources
Connections
Featured Videos

The Bottom Line, Stated First

Because misinformation about “cancer-curing mushrooms” is common, here is the honest summary before any of the details:

Agaricus blazei beta-glucans stimulate anti-tumor immune activity in cell cultures and mice. This is real and reproducible.
In humans, the evidence is limited to small, preliminary studies. The most-cited trial measured natural killer (NK) cell activity and quality of life in patients also receiving chemotherapy — not tumor response or survival.
No trial has shown that Agaricus blazei shrinks tumors, prolongs survival, or cures cancer in people.
It is studied as a possible complementary (adjunct) supportive agent, never as a treatment or substitute for surgery, chemotherapy, radiation, or immunotherapy.
There are documented reports of serious liver injury in cancer patients taking Agaricus supplements, so the risk side of the ledger is not zero.

Back to Table of Contents

Why This Mushroom Became a Cancer-Research Subject

Agaricus blazei entered cancer research through a combination of folklore and immunology. The mushroom was popularized after mid-20th-century reports of low rates of certain diseases among rural Brazilian communities that ate it, and it arrived in Japan during a period of intense scientific interest in mushroom polysaccharides. That interest was legitimate: two other mushroom-derived beta-glucans, lentinan (from shiitake) and PSK/krestin (from turkey tail), had been developed into approved adjunct cancer therapies in Japan, given alongside standard treatment to support the immune system.

Against that backdrop, researchers asked whether Agaricus blazei, which is especially rich in branched beta-glucans, might have similar immune-adjunct properties. The scientific rationale was reasonable. The problem is that public marketing raced far ahead of the evidence, turning a legitimate research question into exaggerated cure claims that the data have never supported.

Back to Table of Contents

Preclinical Evidence: Cell and Animal Tumor Models

The majority of the cancer literature on Agaricus blazei is preclinical. Key findings include:

A soluble proteoglucan fraction produced a selective tumoricidal effect in laboratory studies, an effect the authors attributed to activation of NK cells and induction of apoptosis (programmed cell death) in tumor cells rather than direct chemical toxicity.
A low-molecular-weight antitumor polysaccharide showed immunostimulatory and antitumor activity in mice bearing Sarcoma 180, a standard transplantable mouse tumor used to screen candidate agents.
Broader reviews of beta-glucan biology describe antitumor effects operating through both immune enhancement and antioxidant activity.

These are meaningful mechanistic results, but two limits must be kept in mind. First, mouse tumor models such as Sarcoma 180 are screening tools; a great many agents that shrink Sarcoma 180 have gone on to fail in human cancer. Second, the doses and delivery (often injected, or fed at high relative doses) do not map neatly onto a person eating mushroom extract. Preclinical promise is a reason to keep studying something, not evidence that it works in people.

Back to Table of Contents

The Proposed Mechanism: Immunity, Not Direct Cytotoxicity

It is important to understand how researchers propose the mushroom might help, because it shapes what is plausible. Agaricus blazei beta-glucans are not chemotherapy; they do not poison dividing cells. The proposed anti-tumor mechanism is indirect and immunological: the glucans activate macrophages, dendritic cells, and NK cells (detailed on the Immune Support page), and those activated immune cells may then recognize and attack tumor cells or improve the response to other therapy.

This “biological response modifier” framework is the same one behind the approved mushroom adjuncts lentinan and PSK. It makes Agaricus blazei a candidate supportive agent — something that might help the immune system alongside real treatment — rather than a candidate stand-alone therapy. Even in the best case, the mechanism does not support the idea of a mushroom replacing cancer treatment.

Back to Table of Contents

Chemoprevention and Genotoxicity Studies

A separate strand of research asks whether Agaricus blazei might help prevent cancer-initiating DNA damage rather than fight established tumors. In cell studies, a beta-glucan from Agaricus blazei reduced the genotoxic (DNA-damaging) effects of benzo[a]pyrene — a carcinogen found in smoke and char — in human liver-derived HepG2 cells. In a rat model, dietary Agaricus blazei reduced the development of preneoplastic liver foci (early precancerous lesions).

These chemoprevention findings are interesting and consistent with the mushroom's antioxidant activity. But they are early-stage: reducing a precancerous marker in a rat or protecting a cell line from a chemical is a long way from preventing cancer in a person. No human chemoprevention trial supports a cancer-prevention claim.

Back to Table of Contents

A Mixed Picture: When the Mushroom Did Nothing

Honest science means reporting the negative results too, and Agaricus blazei has them. In the same rat liver-carcinogenesis system where some studies found protection, at least one well-conducted study reported that Agaricus blazei (Himematsutake) did not alter the development of chemically-initiated hepatic preneoplastic foci. Results in these models have depended on the extract, dose, timing, and protocol.

This inconsistency is a feature of the whole field, not a flaw in a single paper. When effects appear in some studies and vanish in others depending on the preparation, it is a sign that the biology is real but weak, sensitive to conditions, and not yet reduced to a reliable, reproducible intervention. That is exactly the situation with Agaricus blazei and cancer.

Back to Table of Contents

The Human Trial People Cite — and Its Limits

The human study most often referenced is a trial in women with gynecological cancers (cervical, ovarian, and endometrial) undergoing chemotherapy, who were given an Agaricus blazei Murill extract or placebo alongside their treatment. The reported findings were higher measured NK-cell activity and improved self-rated quality of life (including fewer chemotherapy side effects such as appetite loss and weakness) in the extract group.

Read carefully, here is what that trial does and does not establish:

It does establish a measurable immune-marker change (NK activity) and a patient-reported quality-of-life signal in people already receiving standard chemotherapy.
It does not establish longer survival, better tumor response, or cure. Those outcomes were not the primary endpoints and were not demonstrated.
Its limits include small size, a single-study status without large independent replication, and the usual challenges of quality-of-life measurement. NK-cell activity is a laboratory surrogate; higher numbers do not automatically translate into better cancer outcomes.

The most accurate summary is that this trial is a reason for further research into Agaricus blazei as a supportive agent during chemotherapy — not evidence that it treats the cancer itself.

Back to Table of Contents

What the Research Does NOT Show

It does not show that Agaricus blazei cures or shrinks any human cancer.
It does not show that the mushroom can replace surgery, chemotherapy, radiation, or immunotherapy.
It does not show a survival benefit in any randomized human trial.
It does not show that “natural” equals safe — see the liver-injury reports below.

Anyone marketing Agaricus blazei as a cancer cure is going far beyond the evidence. The legitimate research question is narrow and supportive; the marketing claims are broad and unproven.

Back to Table of Contents

Safety in Cancer Patients (Including Liver Injury)

The risk side matters especially for cancer patients, who may be tempted toward high-dose supplements. A published case report describes severe hepatic (liver) dysfunction in cancer patients that may have been induced by an Agaricus health-food product. Chemotherapy is itself hard on the liver, and adding a supplement with its own hepatotoxic potential can compound the risk. This paradox — a mushroom with a hepatoprotective reputation in animal studies but real-world liver-injury reports — is examined in detail on the Liver & Antioxidant page.

Additional concerns: theoretical interactions with chemotherapy and immunotherapy, unknown effects on hormone-sensitive cancers, heavy-metal accumulation in Agaricus mushrooms, and the simple danger of a patient delaying or declining effective treatment in favor of an unproven supplement.

Back to Table of Contents

Talking With Your Oncology Team

If you are living with cancer and considering Agaricus blazei, the single most important step is to tell your oncologist and pharmacist before taking it. Bring the actual product. Ask specifically about interactions with your regimen and about monitoring liver function. Reputable cancer centers maintain evidence-based herb databases (such as Memorial Sloan Kettering's About Herbs) precisely so patients and clinicians can have this conversation with accurate information.

Using a supplement alongside a treatment plan your team knows about is very different from using it instead of treatment or in secret. The first can sometimes be accommodated safely; the second two are where people get hurt.

Back to Table of Contents

Key Research Papers

Ahn WS, et al. (2004). Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. International Journal of Gynecological Cancer. — PubMed PMID: 15304151
Fujimiya Y, et al. (1998). Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunology, Immunotherapy. — PubMed PMID: 9625538
Niu YC, et al. (2009). Immunostimulatory activities of a low molecular weight antitumoral polysaccharide isolated from Agaricus blazei Murill (LMPAB) in Sarcoma 180 ascitic tumor-bearing mice. Die Pharmazie. — PubMed PMID: 19694186
Gu Y, et al. (2008). Tumoricidal effects of beta-glucans: mechanisms include both antioxidant activity plus enhanced systemic and topical immunity. Nutrition and Cancer. — PubMed PMID: 18791933
Angeli JP, et al. (2009). Beta-glucan extracted from the medicinal mushroom Agaricus blazei prevents the genotoxic effects of benzo[a]pyrene in the human hepatoma cell line HepG2. Archives of Toxicology. — PubMed PMID: 18528685
Pinheiro F, et al. (2003). Chemoprevention of preneoplastic liver foci development by dietary mushroom Agaricus blazei Murrill in the rat. Food and Chemical Toxicology. — PubMed PMID: 12963007
Barbisan LF, et al. (2003). Agaricus blazei (Himematsutake) does not alter the development of rat diethylnitrosamine-initiated hepatic preneoplastic foci. Cancer Science. — PubMed PMID: 12708495
Barbisan LF, et al. (2003). Effects of crude extracts of Agaricus blazei on DNA damage and on rat liver carcinogenesis induced by diethylnitrosamine. Genetics and Molecular Research. — PubMed PMID: 14966678
Hetland G, et al. (2011). The mushroom Agaricus blazei Murill elicits medicinal effects on tumor, infection, allergy, and inflammation through its modulation of innate immunity and amelioration of Th1/Th2 imbalance and inflammation. Advances in Pharmacological Sciences. — PubMed PMID: 21912538
Hetland G, et al. (2008). Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer. Scandinavian Journal of Immunology. — PubMed PMID: 18782264
Mukai H, et al. (2006). An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Japanese Journal of Clinical Oncology. — PubMed PMID: 17105737